Platelet count >= ,/mcL
Platelet count > ,/mcl
Platelet count >  k/mcL
Platelet count > , cells/mcL
Platelet count >= ,/mcL
Platelet count >= ,/mcL
Platelets ?,/mcL (non-transfused platelet count)
Platelet count >= ,/mcL
Platelet count >= ,/mcL, within  days of starting therapy
Platelet < ,/mcL
Platelet count >=  k/mcl, obtained within  days prior to first study treatment
Thrombocytosis defined as platelet count > ,,/mcL
Platelet >= , / mcL
Platelet count >= /mcL
Platelet count >/=, cells/mcL, or >/=, cells/mcL if more than % bone marrow involvement (Cohorts A, B, D, E, F)
Platelet count >= ,/mcL
PHASE II: Platelet count >= ,/mcL
Platelet count >= ,/mcL
Platelet count >= ,/mcL
Platelet > , mcL
Platelet count <  K/mcL
REGISTRATION TO TREATMENT (STEP ): Platelet count >= , /mcL, within  days prior to first dose of pembrolizumab
REGISTRATION TO TREATMENT (STEP ): Platelet count >= , /mcL, within  days prior to first dose of pembrolizumab
Platelet count > ,/mcL
Platelet count > ,/mcL
Platelet count >= , cells/mcL
Platelet count <  K/mcL at time of enrollment
Platelet count > , cells/mcL (  ^/L)
Platelet count >= ,/mcL
Platelet count >= ,/mcl
Platelet count >=  K/mcL
Platelet count >= ,/mcL
Platelet count >= ,/mcL
Platelet count >= ,/mcl
Platelet count of at least , per mcL
Platelet count >= ,/mcL
Most recent platelet count prior to surgery < ,/mcl
Platelet count > ,/mcL
Thrombocytopenia:\r\n* Defined as platelet count < ,/mcL\r\n* The patient will have had at least  complete blood counts (CBC) with platelet counts < ,/mcL separated by at least  weeks, and no platelet count >= ,/mcL in the prior  week period, despite () delay or () modification of chemotherapeutic regimen\r\n* A platelet count of > ,/mcL, that follows within  days of a platelet transfusion, will not make the patient ineligible, as long as one or more subsequent platelet counts confirms thrombocytopenia (< ,/mcL)\r\n* Patients have undergone bone marrow aspirate and biopsy, or peripheral blood test in the prior  months, without evidence of leukemia or myelodysplasia by fluorescent in situ-hybridization (FISH)\r\n* Dysplastic changes, based on morphology only, will not exclude the patient if FISH panel for myelodysplastic syndrome (MDS) is normal
Platelet count >= ,/mcL
Platelet count >= ,/mcL
Platelet count <,/mcL.